Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAW0R7)

• Drug Name: PELARGONIDIN CHLORIDE Drug Info
• Synonyms: Pelargonidin chloride; Pelargonidin; 134-04-3; Pelargonidol chloride; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-1-benzopyrylium chloride; UNII-DFL6200791; 3,4',5,7-Tetrahydroxyflavylium chloride; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)benzopyrylium chloride; CHEBI:28510; DFL6200791; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromenylium chloride; 1-Benzopyrylium, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-, chloride; CHEMBL591036; 2-(4-hydroxyphenyl)chromenylium-3,5,7-triol chloride; C15H11O5.Cl; EINECS 205-127-7; pelargonidine chloride

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 67249
  ChEBI ID: CHEBI:28510
  CAS Number: CAS 134-04-3
  TTD Drug ID: DMAW0R7

Molecule-Related Drug Atlas

Drug(s) Targeting Lactoylglutathione lyase (GLO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[4]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[4]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[5]
KAEMPFEROL	DMHEMUB	Discovery agent	N.A.	Investigative	[4]
S-(N-butyl-N-hydroxycarbamoyl)glutathione	DMU7EQV	Discovery agent	N.A.	Investigative	[6]
S-(N-heptyl-N-hydroxycarbamoyl)glutathione	DMV6T1Q	Discovery agent	N.A.	Investigative	[6]
S-(N-propyl-N-hydroxycarbamoyl)glutathione	DMRFKZ6	Discovery agent	N.A.	Investigative	[6]
S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione	DM1AHIW	Discovery agent	N.A.	Investigative	[5]
S-(N-pentyl-N-hydroxycarbamoyl)glutathione	DM4E9J2	Discovery agent	N.A.	Investigative	[6]
S-(N-methyl-N-hydroxycarbamoyl)glutathione	DM1C9W3	Discovery agent	N.A.	Investigative	[6]

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[7]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[7]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[7]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[8]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[9]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[10]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[11]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[12]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[13]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[14]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[15]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[16]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[17]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[18]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[19]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[20]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[21]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[22]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[23]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[24]

Drug(s) Affected By Aryl hydrocarbon receptor (AHR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[25]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[26]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[27]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[28]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[29]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[30]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[31]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[32]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[33]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[34]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lactoylglutathione lyase (GLO1)	TTV9A7R	LGUL_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem. 2010 Oct 1;18(19):7029-33.
• [2] Effects of anthocyanins on the AhR-CYP1A1 signaling pathway in human hepatocytes and human cancer cell lines. Toxicol Lett. 2013 Jul 31;221(1):1-8.
• [3] Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T. Toxicol Lett. 2013 Apr 26;218(3):253-9.
• [4] Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75.
• [5] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [6] Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6.
• [7] In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
• [8] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [9] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [10] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [11] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [12] Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
• [13] Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
• [14] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [15] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [16] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [17] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [18] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [19] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [20] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [21] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [22] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [23] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [24] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [25] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [26] Oxidative stress modulates expression of immune checkpoint genes via activation of AhR signaling. Toxicol Appl Pharmacol. 2022 Dec 15;457:116314. doi: 10.1016/j.taap.2022.116314. Epub 2022 Nov 9.
• [27] Profiling of enantiopure drugs towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. Chem Biol Interact. 2014 Feb 5;208:64-76. doi: 10.1016/j.cbi.2013.11.018. Epub 2013 Dec 6.
• [28] Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
• [29] Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2008 Mar 1;122(5):990-8.
• [30] Quercetin, quercetin glycosides and taxifolin differ in their ability to induce AhR activation and CYP1A1 expression in HepG2 cells. Phytother Res. 2012 Nov;26(11):1746-52.
• [31] Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic aryl hydrocarbon receptor pathway. Chem Res Toxicol. 2015 May 18;28(5):907-18.
• [32] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [33] Expression and inducibility of cytochrome P450s (CYP1A1, 2B6, 2E1, 3A4) in human cord blood CD34(+) stem cell-derived differentiating neuronal cells. Toxicol Sci. 2012 Oct;129(2):392-410.
• [34] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.